Nonmyeloablative stem cell transplantation for congenital immunodeficiencies

Blood

Volumn 96, Issue 4, 2000, Pages 1239-1246

  Amrolia, P ^a   Gaspar, H B ^a   Hassan, A ^a   Webb, D ^a   Jones, A ^a   Sturt, N ^a   Mieli Vergani, G ^a   Pagliuca, A ^a   Mufti, G ^a   Hadzic, N ^a   Davies, G ^a   Veys, P ^a  

^a Great Ormond Str Hosp Sick Child ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYADENOSINE TRIPHOSPHATE; FLUDARABINE; LYMPHOCYTE ANTIBODY; MELPHALAN;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HUMAN; IMMUNE DEFICIENCY; INFANT; MALE; NEUTROPENIA; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 0034663152     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.4.1239     Document Type: Article

References (20)

1. Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies
2. Bone marrow transplantation in congenital immunodeficiency diseases
3. Bone marrow 'boosts' following T cell-depleted haploidentical bone marrow transplantation
4. Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency
5. European experience of bone-marrow transplantation for severe combined immunodeficiency
6. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: A European retrospective study of 116 patients
7. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
8. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
9. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
10. Engraftment kinetics after non-myeloablative allogeneic peripheral blood stem cell transplants: Full donor T-cell chimerism precedes alloimmune responses
11. Induction of mixed chimerism and potent anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched and mismatched donor bone marrow transplantation for refractory hematologic malignancies
12. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporin and mycophenolate mofetil after transplant
13. Mixed lympohaematopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation
14. Non-myeloablative transplant regimen used for induction of multi-lineage allogeneic hematopoietic mixed donor-host chimerism in patients with T-cell immunodeficiency
15. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
16. Regimen-related toxicity in patients undergoing bone marrow transplantation
17. Mixed lymphohematopoietic chimerism in adult recipients following non-myeloablative therapy and HLA-matched or mismatched donor bone marrow transplantation, and the effect of donor lymphocyte infusions
18. Epstein-Barr virus-associated B cell lymphoroliferative disease after non-myeloablative allogeneic stem cell transplantation
19. Allogeneic non-myeloablative stem cell transplantation as an emerging new modality for immunotherapy of hematologic malignancies and non-malignant disorders
20. Comparison of immune reconstitution after unrelated and related T-cell depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions